Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
The new autoinjector delivers an IV-equivalent 80 mg furosemide dose at home, and MannKind paired the approval with …
The Series A financing backs a monoclonal antibody licensed from a Chinese biotech, betting that blocking a different …
The supplemental approval for exagamglogene autotemcel gives families of children with recurrent vaso-occlusive crises a one-time gene-editing option …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
First 16-week data from the APEX Part A trial reveal APG777 could raise the bar for biologics in …
Already a subscriber? Log in